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ABSTRACT
Objective: To describe the prevalence and phenotypic
characteristics of small eyes in the European Prospective
Investigation of Cancer (EPIC)-Norfolk Eye Study.
Design: Community cross-sectional study.
Setting: East England population (Norwich, Norfolk and
surrounding area).
Participants: 8033 participants aged 48–92 years old
from the EPIC-Norfolk Eye Study, Norfolk, UK with axial
length measurements. Participants underwent a
standardised ocular examination including visual acuity
(LogMAR), ocular biometry, non-contact tonometry,
autorefraction and fundal photography. A small eye
phenotype was defined as a participant with one or both
eyes with axial length of <21 mm.
Outcome measures: Prevalence of small eyes,
proportion with visual impairment, demographic and
biometric factors.
Results: Ninety-six participants (1.20%, 95% CI 0.98%
to 1.46%) had an eye with axial length less than 21 mm,
of which 74 (77%) were women. Prevalence values for
shorter axial lengths were <20 mm: 0.27% (0.18% to
0.41%); <19 mm: 0.17% (0.11% to 0.29%); <18 mm:
0.14% (0.08% to 0.25%). Two participants (2.1%) had
low vision (presenting visual acuity >0.48 LogMAR) and
one participant was blind (>1.3 LogMAR). The
prevalence of unilateral visual impairment was higher in
participants with a small eye. Multiple logistic regression
modelling showed presence of a small eye to be
significantly associated with shorter height, lower body
mass index, higher systolic blood pressure and lower
intraocular pressure.
Conclusions: The prevalence of people with small eyes
is higher than previously thought. While small eyes were
more common in women, this appears to be related to
shorter height and lower body mass index. Participants
with small eyes were more likely to be blind or to have
unilateral visual impairment.
INTRODUCTION
The small eye phenotype ranges from
anophthalmos to nanophthalmos and
microphthalmos. The latter two conditions
are typically considered to be synonymous1
and are subdivided into simplex2 and
complex3 depending on the presence of
other associated ocular or systemic abnormal-
ities. There is minimal adult data on the
prevalence of this phenotype with estimated
birth prevalences for microphthalmos being
0.002–0.017%;4 and 0.009% for microphthal-
mos in China from mass screening pro-
grammes.5 Data from a hospital cohort
suggest that patients with simple microphthal-
mos comprise between 0.05% and 0.11%
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ophthalmic patients.6 There is great heterogeneity in the
deﬁnition of nanophthalmos and microphthalmos which
complicates interpretation of previous studies,2 7–12 with
a deﬁnition by axial length (AL) <21 mm being the
most inclusive.10–12 Nanophthalmos/microphthalmos is
associated with angle closure glaucoma;1 13 and also with
signiﬁcant visual morbidity. In a recent series of
nanophthalmic individuals from a Melanese population
almost half had either unilateral or bilateral visual impair-
ment.11 There is a paucity of data for comparison. In view
of this, we report data on the prevalence and characteris-
tics of small eyes in British adults in the European
Prospective Investigation of Cancer (EPIC)-Norfolk Eye
Study, and review the deﬁnitions used for microphthal-
mos and nanophthalmos.
METHOD
EPIC is a pan-European study that started in 1989 with
the primary aim of investigating the relationship between
diet and cancer risk.14 The aims of the EPIC-Norfolk
cohort were subsequently broadened to include add-
itional endpoints and exposures such as lifestyle and
other environmental factors.15 The EPIC-Norfolk cohort
was recruited between 1993 and 1997 and comprised
25 639 predominantly white European participants aged
40–79 years. The third health examination was carried
out between 2006 and 2011 with the objective of investi-
gating various physical, cognitive and ocular characteris-
tics of participants then aged 48–92 years.16 The third
health examination was reviewed and approved by the
East Norfolk and Waverney NHS Research Governance
Committee (2005EC07L) and the Norfolk Research
Ethics Committee (05/Q0101/191) and was performed
in accordance with the principles of the Declaration of
Helsinki. All participants gave written, informed consent.
All EPIC-Norfolk Eye Study participants underwent a
detailed health examination performed by trained
nurses following standard operating procedures. Ocular
biometry was measured by non-contact partial coher-
ence interferometry using the Zeiss IOLMaster Optical
Biometer (IOLMaster, Carl Zeiss Meditech Ltd, Welwyn
Garden City, UK). Five measurements of AL as well as
anterior chamber depth (ACD, deﬁned as corneal epi-
thelium to anterior crystalline lens surface) and three
measurements of central keratometry were made to
allow calculation of mean values. Refractive error was
measured using an autorefractor (Model 500,
Humphrey Instruments, San Leandro, California, USA).
Three intraocular pressure (IOP) measurements were
made for each participant using the non-contact Ocular
Response Analyzer (ORA, Reichert Inc, Depew, New
York, USA) and the mean Goldmann correlated IOP
(IOPg) calculated. Visual acuity was measured under
standardised conditions at 4 m using participants’
normal method of distance vision correction and
recorded on the LogMAR scale. Fundal photographs
were taken of both eyes using a TRC-NW65 non-
mydriatic retinal camera (Topcon Corporation, Tokyo,
Japan) with Nikon D80 camera (Nikon Corporation,
Tokyo, Japan). A masked, expert grader from the
Moorﬁelds Grading Centre measured vertical cup–disc
ratio (VCDR). Systolic and diastolic blood pressures
(BPs) were taken from the right arm with the partici-
pant seated for 5 min. A stadiometer was used to record
participant height to the nearest 0.1 cm and weight was
measured to the nearest 0.1 kg using a body compos-
ition analyser (Tanita model TBF 300 s, Chasmors Ltd,
London, UK). Self-reported data on education, occupa-
tion, alcohol intake and smoking status were recorded
by questionnaire.
A small eye was deﬁned by an AL of <21 mm in at
least one eye in keeping with the broadest previously
accepted deﬁnition for microphthalmos/nanophtahla-
mos10–12 and being equivalent to 2SD below the popula-
tion mean value.17 All investigations were performed on
both eyes of each participant and the data from the eye
with lower AL used for analyses at the participant level,
with the exception of visual impairment classiﬁcation
where data from both were used. Visual impairment was
deﬁned by the presenting vision in accordance with the
International Classiﬁcation of Diseases Update and
Revision 200618 and the WHO, which formally com-
prises categories 1–5 with categories 3–5 being blind-
ness. To allow comparison with previous publications we
deﬁned blindness as a presenting visual acuity ≥1.3
logMAR in the better eye and low vision as a presenting
visual acuity of >0.48 in the better eye (ie, combination
of moderate and severe visual impairment categories).
Unilateral visual impairment was deﬁned by using the
eye with worse presenting visual acuity.
Statistical analysis was performed using SPSS V.20.
Testing of normality was performed by the Kolmogorow-
Smirnov method. Comparisons between participants
with and without previous lens extraction were per-
formed using the independent samples t test or
Mann-Whitney U test. Logistic regression was used to
identify factors associated with presence of a small eye
and Fisher’s exact test to compare presence of visual
impairment with the presence of a small eye.
RESULTS
Partial coherence interferometry data were available on
15 881 eyes of 8033 participants, of which 4442 partici-
pants were women (55.3%). Case numbers and overall
prevalence values for small eyes stratiﬁed by AL value
are shown in table 1 and ﬁgure 1. Of the 8033 partici-
pants with AL data, visual acuity measurements were
available on 8016 (99.8%).
Of the 96 participants, 20 were pseudophakic in both
eyes, 6 were pseudophakic in one eye, 1 was aphakic in
both eyes (congenital cataracts and nystagmus) and 1
aphakic in one eye and pseudophakic in the other.
Deﬁned by smallest eye, 26 participants had undergone
previous lens extraction. Fourteen participants (15%)
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had a history of amblyopia or previous squint surgery.
Seven participants (7%) had a history of previous laser
iridotomy or surgical iridectomy. Table 2 shows the
demographic and biometric characteristics of those with
AL <21 mm.
Analysis of the difference in AL between eyes showed
a bimodal distribution (ﬁgure 2) with 19 participants
(20%) comprising the second peak with a mean AL dif-
ference of 5.63 mm (SD 0.97) compared with 77 partici-
pants in the ﬁrst peak with mean AL difference of
0.45 mm (SD 0.39).
Both univariable and multiple variable regression ana-
lyses investigating ocular biometric parameters in phakic
eyes showed small eyes were associated with shallower
ACD, steeper corneal keratometry and higher spherical
equivalent (all p<0.001, table 3). Separate analyses were
performed for other, non-ocular biometric parameters.
For these, univariable logistic regression analyses showed
female sex (OR 2.75, p<0.001), height (per 10 cm, OR
0.46, p<0.001), weight (per 10 kg, OR 0.60, p<0.001,
body mass index (BMI, OR 0.68, p=0.005) and systolic
BP (per 10 mm Hg, OR 1.11, p=0.029) were associated
with the presence of a small eye. Multiple variable logis-
tic regression models showed shorter height, lower BMI,
higher systolic BP and lower IOP to be independent pre-
dictors of a small eye (table 3).
Optic disc grading was possible on both eyes of 61/96
(64%) participants and at least one eye of 82/96 (85%)
participants (right eyes: 12 missing, 9 ungradable; left eyes:
14 missing, 14 ungradable). Three participants (3/61,
4.9%) had VCDR asymmetry of 0.2 or more, and one add-
itional participant had an optic disc consistent with glau-
coma (localised absence of neural rim, one eye only),
giving an overall prevalence of 4/61 (6.6%, 95% CI 2.6%
to 15.7%) for glaucomatous optic neuropathy. No eye had
a VCDR of ≥0.6. Five of 96 (5.2%) participants gave a diag-
nosis of ‘glaucoma’ in their medical history, of these only
one had a diagnosis consistent with their optic disc photo-
graphs. Three participants had one optic disc with disc
drusen. There were no cases of macular hypoplasia,
macular schisis, coloboma or any other retinal abnormality
associated with nanophthalmos.
Visual acuity data were available for all 96 participants
and values are shown in table 2. One participant (1%)
was classiﬁed as blind by the WHO deﬁnition (visual
acuity of less than 1.3 logMAR) and 2/96 (2.1%) had
any degree of visual impairment. Using a deﬁnition of
visual impairment of >0.30 logMAR in the better eye to
allow comparison with previous visual impairment
studies, the prevalence was 5/96 (5.2%). The prevalence
of blindness was signiﬁcantly higher in EPIC-Norfolk
participants with at least one eye of AL <21 mm com-
pared with those without, while the overall prevalence of
low vision was similar (table 4). Unilateral visual impair-
ment by all deﬁnitions was more common in
EPIC-Norfolk participants with at least one small eye
compared with those without (p≤0.001, table 4).
DISCUSSION
There are minimal data describing the prevalence or
characteristics of small eyes. In the EPIC-Norfolk Eye
Study, the prevalence of a participant with an eye of AL
of <21 mm was 1.20%, and 0.27% for those with an eye
of AL <20 mm. Relative to existing data with estimated
birth prevalences for microphthalmos between 0.002%
and 0.017%;4 5 and the prevalence of simple micro-
phthalmos in hospital ophthalmic patients being
Table 1 Number of participants/eyes and overall prevalence values (with 95% CIs) by axial length (mm)
Axial length (mm)
Analysis by participant Analysis by eyes
Number Prevalence (95% CI) Number Prevalence (95% CI)
<21.00 96 1.195% (0.980 to 1.457) 132 0.831% (0.702 to 0.985)
<20.50 47 0.585% (0.441 to 0.777) 57 0.359% (0.277 to 0.465
<20.00 22 0.274% (0.182 to 0.414) 24 0.151% (0.102 to 0.225)
<19.00 14 0.174% (0.105 to 0.292) 14 0.088% (0.053 to 0.148)
<18.00 11 0.137% (0.077 to 0.245) 11 0.069% (0.039 to 0.124)
<17.00 4 0.050% (0.020 to 0.127) 4 0.025% (0.010 to 0.065)
<16.00 1 0.012% (0.003 to 0.069) 1 0.006% (0.002 to 0.035)
<15.00 1 0.012% (0.003 to 0.069) 1 0.006% (0.002 to 0.035)
Figure 1 Graph showing the prevalence of an axial length
less than the value shown at the participant level (defined by
eye with shortest axial length), and at the eye level.
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between 0.05% and 0.11%;6 small eyes are more
common than previously reported.
Nanophthalmos is traditionally associated with a high
prevalence of angle closure glaucoma1 13 and both
nanophthalmos and primary angle closure glaucoma
have similar ocular phenotypes including a short AL,
shallow anterior chamber, hyperopia, small radius of
corneal curvature and a thick crystalline lens. In this
study, the prevalence of glaucomatous optic neuropathy
was estimated to be 6.6% in small eyes based on CDR,
CDR asymmetry or rim abnormalities consistent with
glaucoma. Othman et al19 reported that 12/22 (55%)
nanophthalmic individuals had occludable anterior
chamber angles or glaucoma. In the case series by Tay
et al11 of 17 individuals with nanophthalmos, no data on
glaucoma prevalence are reported. For comparison, the
prevalence of glaucoma (open angle and closed angle
combined) has been estimated to be 2.4% in European
populations.20 We did not calculate VCDR percentiles
for the overall EPIC cohort as per the International
Society Geographical & Epidemiological Ophthalmology
deﬁnition of glaucoma;21 however, no small eye in our
series had a VCDR of ≥0.60. Crowston et al22 reported
optic disc size adjusted VCDR percentiles from the Blue
Mountains Eye Study and showed that for small discs
(1.2 mm vertical diameter) in non-glaucomatous eyes,
the 97.5th centile for VCDR was 0.60 (99th centile: 0.62)
while corresponding values for large optic discs (1.9 mm
diameter) were 0.75 and 0.83, respectively. Thus our
prevalence of 6.6% should be considered as a minimum
prevalence estimate for glaucoma in small eyes, and is
likely to include those at highest risk for visual impair-
ment over their lifetime.21
Review of recent studies reporting on nanophthal-
mos/microphthalmos shows great heterogeneity in the
deﬁnitions used, with cases deﬁned primarily by short
AL with for example, values of <21,10–12 <20.9,2 <20.5,7
<20,8 <18,2 or <17 mm.9 The original description of
nanophthalmos (or pure microphthalmos) by
Duke-Elder1 is an eye ‘reduced in volume without the
presence of other gross congenital abnormalities,’
‘typical dimensions are 16–18.5 mm sagittal,’ ‘hyperopia
is the rule’ and ‘the anterior chamber is typically
shallow.’ The partial relaxation of the deﬁnition to its
currently accepted form (of at least an AL of <21 mm) is
likely due to the rarity of the condition. If an abnormally
short eye is deﬁned based on the lower 2SD and 3SD
limits of mean population ALs, then the calculated
limits are approximately 21 and 20 mm, respectively.16 In
a previous study by our group investigating complica-
tions in small eyes (<21 mm) undergoing phacoemulsiﬁ-
cation and lens implantation, only AL and the presence
of abnormal IOP remained signiﬁcant predicators of
any complication in multiple variable regression ana-
lysis.12 Complications were 15 times more likely in cases
Table 2 Demographic and biometric data presented as mean values with (standard deviation and range min: max value
(range for all participants only)), with [median values, IQR] shown for AL & ACD only
All, axial length <21 mm Phakic Previous lens extraction p Value
Number 96 70 26 –
Age (years) 69.0 (8.8, 50.9 to 89.2) 66.3 (7.5) 76.5 (7.6) <0.001
Sex 22M/74F 13M/57F 9M/17F 0.11
AL (mm) 20.05 (1.26, 14.27 to 20.98)
[20.53, 0.80]
20.45 (0.85)
[20.61, 0.48]
18.96 (1.55)
[18.91, 2.85]
<0.001
ACD (mm) 2.94 (0.69)
[2.75, 0.78]
2.67 (0.44)
[2.62, 0.44]
3.75 (0.71)
[3.98, 0.92]
<0.001
Mean K (D) 45.24 (1.62, 41.71 to 51.19) 45.45 (1.65) 44.64 (1.41) 0.044
SE (D) +3.63 (2.94, −5.50 to +8.38) +5.04 (1.84) −0.15 (1.71) <0.001
Anisometropia, (D) 1.13 (1.23, 0.00 to 6.76) 1.20 (1.27) 0.94 (1.09) 0.37
V/A (logMAR) 0.31 (0.47, −0.20 to 1.68) 0.37 (0.53) 0.16 (0.24) 0.061
LogMAR difference between eyes 0.31 (0.44, 0.00 to 1.82) 0.38 (0.49) 0.12 (0.19) 0.012
IOP (mm Hg) 15.7 (3.8) 15.6 (3.9) 16.0 (3.3) 0.63
Comparisons with p values are between phakic and those with previous lens extraction.
ACD, anterior chamber depth; AL, axial length; IOP, intraocular pressure.
Figure 2 Cumulative frequency distribution of axial length
difference (asymmetry) between eyes for each participant.
Note the bimodal distribution.
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with AL of <20 mm (compared with those 20–21 mm,
p≤0.001). The differential complication rate supports
the previous recommendation by Weiss et al2 that micro-
phthalmos and nanophthalmos should be considered as
two separate phenotypes, based on AL. Based on the
above it would appear reasonable to classify small eyes
into microphthalmos (<21 mm) and nanophthalmos
(<20 mm), respectively.
We found 1% of participants with small eyes were blind
and 2% had low vision. When compared with all
EPIC-Norfolk participants, blindness appears to be more
common in those with a small eye (p=0.036, although case
numbers were very low), but low vision was not (p=0.36).
Unilateral visual impairment (deﬁned by the worse seeing
eye) was more common by all deﬁnitions (p≤0.001).
When compared with data from population studies, the
Table 3 Univariable and multiple variable logistic regression analyses of factors associated with small eyes
OR 95% CI p Value
(A) Ocular biometric parameters: phakic participants
Univariable regression
Anterior chamber depth (per 1 mm) 0.06 0.03 to 0.12 <0.001
Mean keratometry (per 1D) 2.16 1.82 to 2.57 <0.001
Spherical equivalent (per 1D) 2.67 2.35 to 3.03 <0.001
Multiple variable regression
Anterior chamber depth (per 1 mm) 0.02 0.01 to 0.08 <0.001
Mean keratometry (per 1D) 5.97 3.98 to 8.98 <0.001
Spherical equivalent (per 1D) 5.89 4.16 to 8.31 <0.001
(B) Other parameters: all participants
Univariable regression
Age (per decade) 1.06 0.82 to 1.36 0.67
Female sex 2.75 1.70 to 4.43 <0.001
Height (per 10 cm) 0.46 0.36 to 0.58 <0.001
Weight (per 10 kg) 0.60 0.51 to 0.72 <0.001
BMI (per 5 kg/m2) 0.68 0.52 to 0.89 0.005
Social class
Professional Ref
Managerial/technical 0.81 0.39 to 1.69 0.57
Skilled non-manual 0.91 0.40 to 2.09 0.82
Skilled manual 0.95 0.43 to 2.10 0.90
Partly-skilled 1.06 0.44 to 2.53 0.90
Unskilled 1.76 0.53 to 5.77 0.35
Education level
Less than O level Ref
O level 1.31 0.69 to 2.50 0.41
A level 0.94 0.57 to 1.55 0.81
Degree 0.93 0.50 to 1.76 0.83
Systolic blood pressure (per 10 mm Hg) 1.11 1.01 to 1.23 0.029
Diastolic blood pressure (per 10 mm Hg) 0.97 0.78 to 1.20 0.78
Self-reported alcohol intake
No intake Ref
<7 units/week 0.81 0.48 to 1.37 0.43
≥7<14 units/week 0.61 0.33 to 1.13 0.12
≥14<21 units/week 0.61 0.28 to 1.33 0.22
≥21 units/week 0.70 0.38 to 1.28 0.25
Smoking status
Never Ref
Ever 0.85 0.56 to 1.27 0.41
Intraocular pressure (mm Hg) 0.95 0.90 to 1.01 0.09
Multiple variable regression
Age (per decade) 0.89 0.68 to 1.17 0.40
Female sex 0.91 0.47 to 1.77 0.77
Height (per 10 cm) 0.42 0.29 to 0.59 <0.001
BMI (per 5 kg/m2) 0.69 0.53 to 0.90 0.006
Systolic blood pressure (per 10 mm Hg) 1.11 1.01 to 1.22 0.030
Intraocular pressure (mm Hg) 0.93 0.88 to 0.99 0.030
Ref: reference category. For the multiple variable regression models (either A or B), only parameters reaching statistical significance in the
respective univariable analysis were included, and only those in the final model shown.
BMI, body mass index.
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prevalence of visual impairment in EPIC-Norfolk partici-
pants is low overall, and values in those with small eyes are
again low or similar. In the Blue Mountains Eye Study,23
4.6% had a visual acuity of 6/12 (20/40) or less in the
better eye and 14.4% had a visual acuity of 6/12 or less in
their worse eye, whereas in our cohort of small eyes the
equivalent percentages were 5.2% and 30.2%. In the
Salisbury Eye Study, 9% of participants aged 75–84 years
old had a visual acuity of <6/12 in their better eye;24 while
in the MRC study in Britain this value was 15% for those
75–84 years old.25 There is minimal data on visual impair-
ment in nanophthalmic individuals, with a recent study in
a Melanesia population11 (deﬁnition: AL usually <21 mm
in at least one eye) reporting 5/17 (29%) had bilateral
visual impairment and 9/17 (53%) had unilateral visual
impairment (deﬁned as <6/12 (20/40) Snellen in the
better eye).
We found a marked bimodal distribution in AL differ-
ence between eyes in individuals with small eyes, with
20% individuals having >3.5 mm AL asymmetry. A
bimodal distribution in AL difference has not previously
been described, with Weiss et al2 reporting a difference
of only 0.4 mm or less in a series of 21 patients with
simple microphthalmos.
Our study has a number of limitations; these being
primarily the absence of lens thickness and scleral thick-
ness data to further characterise participants with small
eyes. Additionally participants were not examined on a
slit-lamp, for example, gonioscopy to determine the pres-
ence of an occludable anterior chamber angle (and there-
fore to determine if the glaucomatous optic neuropathy in
our ﬁve cases were in the presence of an open or closed
anterior chamber angle). Our prevalence value for glau-
coma was based on glaucomatous optic neuropathy only
rather than glaucomatous optic neuropathy and visual
ﬁeld defect.21 Comparisons of visual acuities were only per-
formed in EPIC-Norfolk participants in whom ALs were
measurable, and consequently this may have excluded
those with visual impairment or blindness where AL could
not have been measured optically (ie, underestimating
prevalence values). Additionally, those with visual impair-
ment may have self-selected not to participate in the
EPIC-Norfolk Eye Study, thus again underestimating case
numbers.
In summary, the small eye phenotype was more
common than previously reported, and our study provides
prevalence values in British adults. There are no standar-
dised deﬁnitions for microphthalmos or nanophthalmos;
however, based on current evidence, subdivision by AL of
<21 mm for microphthalmos and <20 mm for nanophthal-
mos appears reasonable. People with small eyes appear
more likely to be blind or have unilateral visual impair-
ment. The estimated prevalence of glaucomatous optic
neuropathy in our cohort appeared to be lower than
expected and warrants further investigation.
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